– NETHERLANDS, Utrecht – InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, today announced the appointment of Dr. Andrea van Elsas (Ph.D.)to its Supervisory Board, succeeding Dr. Mark Vaeck who has stepped down from the Supervisory Board.
Dr. van Elsas transitions from the Scientific Advisory Board where he served as a member since February 2019.
“Andrea has been at the forefront of the discovery and development of transformative therapies in the immuno-oncology space and his deep industry know-how has already been invaluable to us over the last two years,” said CEO, Dr. Roel Schaapveld.
He added: “As a member of our Supervisory Board, we will further benefit from his extensive experience as we continue to enroll patients in our ongoing Phase I/Ib study, evaluating our lead candidate, INT-1B3, as well as push forward other therapeutic candidates in our preclinical pipeline.”
About Dr. Andrea van Elsas
Dr. van Elsas is an immuno-oncology expert with over 20 years of experience in advancing highly innovative oncology assets and serves as a venture partner with Third Rock Ventures. Previously, he served as Chief Scientific Officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded in 2011. From 1999 to 2011, he held various positions at Organon, which was acquired by Schering-Plough and later by Merck, in Oss, The Netherlands, and Cambridge, Massachusetts. At Merck, he directed the immuno-oncology portfolio and led the anti-PD1 program that later became known as pembrolizumab. As a postdoctoral researcher, Dr. Van Elsas worked in the lab of 2018 Nobel Laureate Jim Allison at the University of California, Berkeley, and is a co-inventor on the original anti-CTLA-4 patents that formed the basis for the development of ipilimumab, the first checkpoint inhibitor approved in 2011 by the FDA for the treatment of melanoma.
“Over the past two years, it has been great to see how Roel and his team advanced the first lead candidate, INT-1B3, from preclinical proof-of-concept to its clinical evaluation,” commented Dr. Andrea van Elsas. “Its unique Mode of Action positions INT-1B3 as a novel agent affecting multiple aspects of cancer biology with the potential to induce tumor rejection and long-term immunity involving CD8+ effector T cells. My transition to the Company’s Supervisory Board comes at an exciting time, as the Company expects to announce topline clinical results on INT-1B3 from the dose-escalation part of the Phase I/Ib study early next year.”
About InteRNA Technologies
InteRNA is a Dutch clinical-stage biotech company developing a pipeline of proprietary microRNA therapeutics targeting key processes in the initiation and progression of human diseases, with a focus on cancer. Selected through InteRNA’s leading miRNA discovery and functional validation platform and enabled with a 3rd-generation drug delivery formulation, these miRNA compounds can mount a coordinated anti-cancer attack by engaging multiple signal transduction targets simultaneously. With this approach, we address the high need for novel therapeutics with improved efficacy and less prone to drug-acquired resistance that will benefit cancer patients.
For more information : https://interna-technologies.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
